Angioedemas, Hereditary: all 173 studies

Page 2 of 2. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.

• Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)CompletedNCT06690047Phase 4
• Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEActive, not recruitingNCT06669754Phase 3
• HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)Active, not recruitingNCT06634420Phase 3
• Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With SebetralstatApproved for marketingNCT06628713
• A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean PeopleCompletedNCT06587464
• Donidalorsen Expanded Access Program for Patients With Hereditary AngioedemaApproved for marketingNCT06415448
• Social Evaluated Cold Pressor Test in Hereditary Angioedema PatientsCompletedNCT06414252
• Autonomic Nervous System Profile in Hereditary AngioedemaCompletedNCT06408805
• A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899
• Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaCompletedNCT06343779Phase 3
• A Long-term Study of STAR-0215 in Participants With Hereditary AngioedemaActive, not recruitingNCT06007677Phase 2
• Status of Dental Care Practices in Patients With Hereditary AngioedemaStatus unknownNCT05776784
• Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema PatientsActive, not recruitingNCT05691361Phase 1/2
• A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in CanadaCompletedNCT05578417
• PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 TrialCompletedNCT05511922Phase 3
• A Survey of Icatibant in Pediatric Participants With Hereditary AngioedemaCompletedNCT05509569
• An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)CompletedNCT05505916Phase 3
• A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at HomeCompletedNCT05489640
• A Study of STAR-0215 in Healthy Adult ParticipantsCompletedNCT05477160Phase 1
• A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)Active, not recruitingNCT05469789
• A Survey of Lanadelumab in Participants With Hereditary AngioedemaActive, not recruitingNCT05397431
• A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)Active, not recruitingNCT05392114Phase 3
• Characterization of Rhythmicity Profiles of Bradykinin-mediated Angioedema Attacks Using a Tracking Smartphone Application.WithdrawnNCT05304091
• A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy VolunteersCompletedNCT05178355Phase 1
• A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in PolandCompletedNCT05147181
• A Gene Therapy Study of BMN 331 in Subjects With Hereditary AngioedemaActive, not recruitingNCT05121376Phase 1/2
• NTLA-2002 in Adults With Hereditary Angioedema (HAE)Active, not recruitingNCT05120830Phase 1/2
• Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) FormulationsCompletedNCT05118958Phase 1
• A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With Hereditary AngioedemaCompletedNCT04957641
• A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in ArgentinaCompletedNCT04955964
• Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary AngioedemaWithdrawnNCT04898309Phase 2/3
• Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary AngioedemaCompletedNCT04888650
• A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term ProphylaxisCompletedNCT04861090
• Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and AdultsNo longer availableNCT04583007
• Safety and Pharmacokinetics of GNR-038 in Healthy VolunteersCompletedNCT04557319Phase 1
• Oral Berotralstat Expanded Access ProgramApproved for marketingNCT04428632
• A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy VolunteersCompletedNCT04349800Phase 1
• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or IICompletedNCT04130191
• Hereditary Angioedema Kininogen AssayTerminatedNCT04091113
• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North AmericaCompletedNCT03845400
• Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and IIStatus unknownNCT03828279
• Patient Registry to Evaluate the Real-world Safety of Ruconest®CompletedNCT03697187
• Epidemiological Analysis for Hereditary Angioedema DiseaseCompletedNCT03558009
• A Relative Bioavailability Study of Two Formulations of BCX7353CompletedNCT03202784Phase 1
• A Drug-Drug Interaction Study to Evaluate Drug Transporter InteractionsCompletedNCT03136237Phase 1
• C1-inhibitor in Allergic ASThma PatientsTerminatedNCT03051698Phase 4
• Biomarker for Hereditary AngioEdema DiseaseCompletedNCT03029728
• The Role of the Coagulation Pathways in Recurrent AngioedemaTerminatedNCT02892682Not applicable
• Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric PopulationTerminatedNCT02854397
• An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe SubstratesCompletedNCT02819102Phase 1
• Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary AngioedemaTerminatedNCT02670720Phase 3
• First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese VolunteersCompletedNCT02448264Phase 1
• Study to Determine How BCX4161 is Metabolized and Eliminated by the BodyCompletedNCT02218294Phase 1
• Hereditary AngioEdema, Neurobiology and PsychopathologyStatus unknownNCT02159430
• A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161CompletedNCT02125162Phase 1
• Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAECompletedNCT01984788Phase 2
• A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy SubjectsCompletedNCT01923207Phase 1
• Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary AngioedemaWithdrawnNCT01832896Phase 2
• EDEMA2: Evaluation of DX-88's Effect in Mitigating AngioedemaCompletedNCT01826916Phase 2
• A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase InhibitorCompletedNCT01760343Phase 1
• A Call Center During HAE Attacks (SOS HAE)CompletedNCT01679912Phase 4
• A European Post-Authorisation Observational Study Of Patients With Hereditary AngioedemaCompletedNCT01541423
• C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) AttacksCompletedNCT01397864
• Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary AngioedemaWithdrawnNCT01253382Phase 2/3
• C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) ExacerbationWithdrawnNCT01151735Phase 4
• Patient Registry Study of Berinert® in Normal Clinical PracticeCompletedNCT01108848
• Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal TransplantationWithdrawnNCT01035593Phase 2
• Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)CompletedNCT01034969
• Berinert P Study of Subcutaneous Versus Intravenous AdministrationCompletedNCT00748202Phase 3
• Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema SubjectsCompletedNCT00432510Phase 1
• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262288Phase 2/3
• Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00261053Phase 2
• Kinetics, Efficacy and Safety of C1-Esteraseremmer-NCompletedNCT00119431Phase 2

← Angioedemas, Hereditary overview